Moleculin Biotech
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Moleculin Biotech generated cash of -$24,101,000, which is more than the previous year. Cash used in financing activities reached the amount of $4,651,000 last year. Net change in cash is therefore -$19,595,000.
Cash Flow
| 2015 | -423.50K | 0 | 451.6K |
|---|---|---|---|
| 2016 | -3.76M | -121.10K | 8.86M |
| 2017 | -7.32M | -28K | 10.05M |
| 2018 | -12.20M | -417K | 12.04M |
| 2019 | -17.19M | -51K | 20.85K |
| 2020 | -17.77M | -374K | 22.54M |
| 2021 | -18.95M | -19K | 74.72M |
| 2022 | -27.63M | -67K | -23K |
| 2023 | -24.10M | -124K | 4.65M |
MBRX Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 43.14M | 70.90M | 15.17M | 10.73M | 7.13M | 7.71M | 5.00M | 28.09K | 0 |
Operating activities | |||||||||
Net income | -29.76M | -29.02M | -15.89M | -17.35M | -13.20M | -11.87M | -9.80M | -3.92M | -748.36K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 127K | 130K | 164K | 200K | 199K | 68K | 18K | 6.16K | 0 |
Stock-based compensation expense | 1.98M | 2.27M | 2.37M | 1.68M | 1.53M | 0 | 707K | 411.47K | 0 |
| Deferred income tax benefit | 1.98M | 2.27M | 2.37M | 1.68M | 1.53M | 0 | 707K | 411.47K | 0 |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 403K | 731K | 235K | -1.02M | 907K | 436K | 411K | -41.12M | 0 |
Cash generated by operating activities | -24.10M | -27.63M | -18.95M | -17.77M | -17.19M | -12.20M | -7.32M | -3.76M | -423.50K |
Investing activities | |||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -124K | -67K | -19K | -376K | -52K | -417K | -28K | -21.47K | 0 |
Acquisitions Net | 0 | 0 | 0 | 2K | 1K | 0 | 0 | -99.63K | 0 |
Cash generated by investing activities | -124K | -67K | -19K | -374K | -51K | -417K | -28K | -121.10K | 0 |
Financing activities | |||||||||
Common Stock Issued | 4.16M | 0 | 74.68M | 22.56M | 19.29M | 12.02M | 6.07M | 9.17M | 1.6K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -23 | -23 | -17 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -469.93K | 450K |
Cash used in financing activities | 4.65M | -23K | 74.72M | 22.54M | 20.85K | 12.04M | 10.05M | 8.86M | 451.6K |
Net Change In Cash | -19.59M | -27.75M | 55.73M | 4.43M | 3.60M | -580K | 2.70M | 4.97M | 28.09K |
Cash at end of period | 23.55M | 43.14M | 70.90M | 15.17M | 10.73M | 7.13M | 7.71M | 5.00M | 28.09K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |